Third Quarter 2020 Earnings October 28, 2020

CAPI

Fluid & Metering

Health & Science

Fire & Safety / Diversified



Trusted Solutions, Improving Lives™

Agenda



IDEX Business Overview

- Q3 Overview
- COVID-19 Opportunities
- End Market Update

Financials

- Q3 Performance
- Operating Profit

Q4 Summary

Q&A



Replay Information



- Dial toll-free: 877.660.6853
- International: 201.612.7415
- Conference ID: #13694806
- Log on to: www.idexcorp.com



Cautionary Statement



Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures

This presentation and discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the anticipated effects of the coronavirus pandemic, including with respect to the Company's revenues, facility closures and access to capital, capital expenditures, acquisitions, cost reductions, cash flow, cash requirements, revenues, earnings, market conditions, global economies, plant and equipment capacity and operating improvements, and are indicated by words or phrases such as "anticipates," "estimates," "plans," "expects," "projects," "forecasts," "should," "could," "will," "management believes," "the company believes," "the company intends," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: the duration of the coronavirus pandemic and the effects of the coronavirus on our ability to operate our business and facilities, on our customers and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries – all of which could have a material impact on order rates and IDEX's results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the "Risk Factors" section included in the company's most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the company's filings with the SEC. The forward-looking statements included in this presentation and discussion are only made as of today's date, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information in this presentation and discussion.

This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the nine-month period ending September 30, 2020, which is available on our website.



Business Update



Q3 Overview





Living with the Virus moving to the New Normal

- Continuing to leverage COVID playbook
- Strong teams delivering globally
- Continued focus on solving our customers' challenges

Business Resilience

- Effectively managing business recovery
- Diversified portfolio balancing declines
- Continued financial strength, strong cash flow


Turning to Offense

- Organic investments made
- Innovative growth in target markets
- Pursuing M&A opportunities



COVID-19 Organic Opportunities







\$25M - \$100M opportunity in COVID-19 applications



COVID-19 Testing

- IDEX Health & Science Microfluidics capabilities are enabling rapid Point-of-Care molecular diagnostic testing for COVID-19
 - The IDEX technology is at the heart of consumable cartridges used within customers POC testing devices
 - These cartridges are a critical component in the push to bring rapid, <u>highly accurate</u> testing solutions to market in the fight against COVID-19
- IH&S also supplies fluidics and optics components and assemblies for multiple instruments used in the testing for COVID-19



Representative model of POC consumable




Market Update

GORPORATION

	FLUID & METERING TECHNOLOGY	HEALTH & SCIENCE TECHNOLOGY	FIRE & SAFETY / DIVERSIFIED
2020 Q3 REVENUE	\$221M	\$220M	\$141M
% OF TOTAL	38%	38%	24%
END MARKETS	1ndustrial	Life Sciences	↑ Dispensing
	Chemical	Analytical Instrumentation	↑ Rescue
	Energy	1 Industrial / Other	Fire
	Water	Food / Pharma	Automotive
	Agriculture	Auto	1 Industrial / Other
		Semiconductor	
	- Change vs Q2		Trusted Solutions Improving Lives™
DEX Proprietary & Confidential	- Down < (5%) vs PY	– Down (5%) – (15%) vs PY	- Down > (15%) vs PY ⁹

Organic Order Performance






Monthly improvement experienced in all segments

Trusted Solutions,

Improving Lives™

Financials






*Operating margin and EPS data adjusted for restructuring expenses (\$2.9M in Q3 2020; \$12.0M in Q3 2019) and inventory step-up (\$3.3M in Q3 2019).

Q3 Adjusted Operating Income Walk





Trusted Solutions, Improving Lives™

Q4 Summary




- Organic revenue expected to be down 3% 5%
- Significant discretionary cost reductions already taken, top line organic flow through ~40%
- Pivoting to offense as core business and cash flow resiliency evident
- Free cash flow conversion greater than 100% of net income




Appendix



Fluid & Metering Technologies





2019 2020

(Dollars in millions)

Q3 Sales Mix:Organic-17%Acquisition8%FX1%Reported Sales-8%

Q3 Highlights:

- □ Industrial & Energy markets remain challenged with moderate recovery in the quarter
- □ Agriculture remained a positive story due to pre-season order strength
- Chemical market soft on delayed projects and investment
- □ Water has remained stable, impacted by some project delays


Volume decline partially mitigated through targeted restructuring and cost control

Trusted Solutions, Improving Lives™

*Operating margin adjusted restructuring expenses (\$.6M in Q3 2020; \$.0M in Q3 2019).


Health & Science Technologies





Operating Margin*

(Dollars in millions)



Q3 Sales Mix:	Organic	-6%
	Acquisition	1%
	FX	_1%
	Reported Sales	-4%

Q3 Highlights:

Q3

■2019 ■2020

- Scientific Fluidics & Optics negatively impacted by declines in AI and IVD, partially offset by COVID related innovative projects
- □ Industrial markets improved due to innovative new product offerings
- □ MPT experiencing strength in Pharma market
- Sealing Solutions saw strengthening in the Semicon and Automotive market, offset by continued weakness in Oil & Gas markets




*Operating margin adjusted for restructuring expenses (\$1.0M in Q3 2020; \$11.2M in Q3 2019) and inventory step-up charge of \$3.3M in Q3 2019.

IDEX Proprietary & Confidential

Trusted Solutions Improving Lives™

Fire & Safety / Diversified Products







Organic	-10%
FX	_1%
Reported Sales	-9%
	FX

Q3 Highlights:

- **□** Fire markets down due to project timing, OEM backlogs remain strong
- Rescue improved year-over-year due to project timing and new product demand
- □ Band-IT showed recovery in the transportation & aerospace
- Dispensing revenues recovered versus Q2 on paint market improvement in Europe



Markets stabilized and showing signs of recovery

*Operating margin adjusted for restructuring expenses (\$1.2M in Q3 2020; \$.1M in Q3 2019).